已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 14714: Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: Open-Label Extension Data From FOURIER

医学 Evolocumab公司 安慰剂 中止 情景记忆 认知功能衰退 不利影响 随机对照试验 内科学 认知 精神科 痴呆 替代医学 疾病 载脂蛋白A1 病理 胆固醇 载脂蛋白B
作者
André Zimerman,Michelle L. O’Donoghue,Xinhui Ran,KyungAh Im,Brian F Ott,François Mach,Kenton H. Zavitz,Christopher E. Kurtz,Maria Laura Monsalvo,Bei Wang,Dan Atar,Anthony Keech,Marc S. Sabatine,Robert P. Giugliano
出处
期刊:Circulation [Ovid Technologies (Wolters Kluwer)]
卷期号:148 (Suppl_1)
标识
DOI:10.1161/circ.148.suppl_1.14714
摘要

Background: Concerns have been raised about low LDL-C levels and possible adverse effects on cognition. PCSK9 inhibitors markedly lower LDL-C, yet EBBINGHAUS, a prespecified substudy within the FOURIER trial, did not show adverse cognitive changes with evolocumab over 19 months median follow-up. Purpose: To investigate the long-term effects of evolocumab on cognitive function. Methods: EBBINGHAUS was a substudy of cognitive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB) within the FOURIER randomized trial of evolocumab vs placebo in patients with established ASCVD. Patients in North America and Europe who completed EBBINGHAUS on study drug were eligible for an open-label extension (OLE) study with evolocumab. The primary endpoint was change in spatial working memory strategy index of executive function score (SWMI) from baseline over time. Secondary endpoints were measures of working memory, episodic memory, and psychomotor speed. A paired t-test was used to compare baseline vs post-baseline scores during OLE. Results: Of 1204 patients from EBBINGHAUS, 306 entered the OLE and were treated with evolocumab for a median of 5.1 years. Median achieved LDL-C was 34 mg/dL (IQR 21-50). No significant change in SWMI occurred during the OLE period overall [mean (±SD) change -0.1±2.7, p=0.73] or when stratified by original randomized allocation ( Figure 1A ). For secondary outcomes, one showed no change during the OLE period, two showed small changes (10-15% of SD), but these were directionally inconsistent (one higher, one lower). In 152 patients originally randomized to evolocumab, there was no significant change in SWMI from randomization through long-term follow-up over a median of 6.7 and a maximum of 7.2 years (mean change 0.1±2.6, p=0.66) ( Figure 1B ). Conclusion: Evolocumab did not lead to any apparent long-term decline in cognitive function through follow-up extending up to 7.2 years.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
英姑应助karstbing采纳,获得10
3秒前
言非离完成签到 ,获得积分10
3秒前
111完成签到,获得积分10
4秒前
小马甲应助刻苦的采文采纳,获得10
4秒前
6秒前
嘿嘿发布了新的文献求助10
8秒前
星辰大海应助山楂采纳,获得10
8秒前
朴实凡柔发布了新的文献求助10
9秒前
积极盼山发布了新的文献求助10
10秒前
αβ发布了新的文献求助10
11秒前
Orange应助酷炫断秋采纳,获得10
11秒前
酷波er应助yiyo采纳,获得10
12秒前
king完成签到,获得积分10
15秒前
人间生巧完成签到,获得积分10
16秒前
chunhe完成签到,获得积分20
17秒前
乔达摩完成签到 ,获得积分10
18秒前
孤独不斜关注了科研通微信公众号
18秒前
共享精神应助dnnnsns采纳,获得10
21秒前
无花果应助zzzz采纳,获得20
22秒前
小不正经完成签到 ,获得积分10
22秒前
111关注了科研通微信公众号
22秒前
庾稀发布了新的文献求助20
23秒前
傻自强呀完成签到,获得积分10
25秒前
积极盼山完成签到,获得积分10
25秒前
ding应助朴实凡柔采纳,获得10
26秒前
MrLee2R发布了新的文献求助30
27秒前
27秒前
尤寄风完成签到,获得积分10
29秒前
29秒前
yyw完成签到 ,获得积分10
30秒前
31秒前
fabius0351完成签到,获得积分10
32秒前
林屿溪完成签到,获得积分10
33秒前
一杯茶发布了新的文献求助10
33秒前
luogrou发布了新的文献求助10
34秒前
36秒前
乔达摩悉达多完成签到 ,获得积分10
37秒前
P_Chem完成签到,获得积分10
37秒前
白小超人完成签到 ,获得积分10
38秒前
高分求助中
Lire en communiste 1000
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 800
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 700
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Becoming: An Introduction to Jung's Concept of Individuation 600
Evolution 3rd edition 500
Die Gottesanbeterin: Mantis religiosa: 656 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3171316
求助须知:如何正确求助?哪些是违规求助? 2822235
关于积分的说明 7938538
捐赠科研通 2482767
什么是DOI,文献DOI怎么找? 1322762
科研通“疑难数据库(出版商)”最低求助积分说明 633722
版权声明 602627